bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 5 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

Low molecular weight cyclin E (LMW-E) expression overcomes exemestane inhibition of proliferation
Supplemental Figure 1 and 2 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

Supplemental Figure 1: Nuclear and cytoplasmic scoring system for cyclin E. Supplemental Figure 2: Breast cancer recurrence-free interval in patients with estrogen receptor-positive comparing positive and negative staining for Ki67
Supplemental FIgure 4 from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Authors: Doostan Iman , Karakas Cansu , Kohansal Mehrnoosh , Low Kwang-Hui , Ellis Matthew J. , Olson John A. , Suman Vera J. , Hunt Kelly K. , Moulder Stacy L. , Keyomarsi Khandan
Published: April 2023

Low molecular weight cyclin E (LMW-E) overcomes cell cycle arrest induced by aromatase inhibitors.
Supplementary Figure S3 from Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Authors: Duran Rafael , Mirpour Sahar , Pekurovsky Vasily , Ganapathy-Kanniappan Shanmugasundaram , Brayton Cory F. , Cornish Toby C. , Gorodetski Boris , Reyes Juvenal , Chapiro Julius , Schernthaner Rüdiger E. , Frangakis Constantine , Lin MingDe , Sun Jessica D. , Hart Charles P. , Geschwind Jean-François
Published: April 2023

Supplementary Figure S3: Treatment related toxicity.
Supplemental Table 3 from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Authors: Craddock Charles F. , Houlton Aimee E. , Quek Lynn Swun , Ferguson Paul , Gbandi Emma , Roberts Corran , Metzner Marlen , Garcia-Martin Natalia , Kennedy Alison , Hamblin Angela , Raghavan Manoj , Nagra Sandeep , Dudley Louise , Wheatley Keith , McMullin Mary Frances , Pillai Srinivas P. , Kelly Richard J. , Siddique Shamyla , Dennis Michael , Cavenagh Jamie D. , Vyas Paresh
Published: April 2023

Table S3. Variants detected by NGS targeted re-sequencing
Supplementary Figure S1-S3 legends from Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Authors: Duran Rafael , Mirpour Sahar , Pekurovsky Vasily , Ganapathy-Kanniappan Shanmugasundaram , Brayton Cory F. , Cornish Toby C. , Gorodetski Boris , Reyes Juvenal , Chapiro Julius , Schernthaner Rüdiger E. , Frangakis Constantine , Lin MingDe , Sun Jessica D. , Hart Charles P. , Geschwind Jean-François
Published: April 2023

Supplementary Figure S1-S3 legends
Supplemental Table 1 from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Authors: Craddock Charles F. , Houlton Aimee E. , Quek Lynn Swun , Ferguson Paul , Gbandi Emma , Roberts Corran , Metzner Marlen , Garcia-Martin Natalia , Kennedy Alison , Hamblin Angela , Raghavan Manoj , Nagra Sandeep , Dudley Louise , Wheatley Keith , McMullin Mary Frances , Pillai Srinivas P. , Kelly Richard J. , Siddique Shamyla , Dennis Michael , Cavenagh Jamie D. , Vyas Paresh
Published: April 2023

Table S1. Details for NGS amplicons
Supplementary Data from Numb−/low Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling
Authors: Guo Yanjing , Zhang Kai , Cheng Chaping , Ji Zhongzhong , Wang Xue , Wang Minglei , Chu Mingliang , Tang Dean G. , Zhu Helen He , Gao Wei-Qiang
Published: April 2023

Supplementary Mehods, Materials, figures and tables Figure S1. Immunofluorescent staining of Numb in PCa tissues. Figure S2. Classical Wnt signaling was not affected by Numb in PCa cells. Figure S3. The mRNA levels of Hes1 and GLI1 negatively correlated with Numb in PCa tissues. Figure S4. Identification of Numb proximal promoter. Figure S5. Notch signaling exerted no significant effect on the transcription of Numb gene. Figure S6. Effects of the treatment of DAPT, cyclopamine, or a combination of DAPT and cyclopamine on the GFP status of Numb-promoter-GFP reporter lentivirus transfected C4-2B cells. Figure S7. Treatment with a combination of DAPT and cyclopamine resulted in a shift of Numb-/low to Numbhigh cells. Figure S8. The percentage of cells with nuclear localized AR protein was significantly lower in Numb-/low PCa cells than Numbhigh cells. Figure S9. Blockage of Notch and Hedgehog signaling by DAPT and cyclopamine significantly enhanced the apoptosis of Numb-/low cells induced by flutamide-mediated androgen deprivation. Supplementary Table 1. Detailed clinical information of human prostate cancer patients in this study Supplementary Table 2. Primer sequences for qRT-PCR Supplementary Table 3. Antibodies used in Apoptosis Assay, Immunoblotting and Immunofluorescence experiments. Supplementary Table 4. shPTCH1 and shNumb sequences. Supplementary Table 5. Information of plasmids components of RBP-Jκ, GLI and TCF/LEF1 luciferase reporter Supplementary Table 6. Information of response elements of RBP-Jκ, GLI and TCF/LEF1 luciferase reporter
Supplementary Table 5 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Association of HLA-DPA1 Expression with Clinical and Biological Characteristics of Uniformly Managed Pediatric Adrenocortical Carcinoma
Supplementary Tables S1 and S2 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Authors: Ma Cynthia X. , Gao Feng , Luo Jingqin , Northfelt Donald W. , Goetz Matthew , Forero Andres , Hoog Jeremy , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Anderson Karen S. , Margenthaler Julie , Aft Rebecca , Hobday Timothy , Moynihan Timothy , Gillanders William , Cyr Amy , Eberlein Timothy J. , Hieken Tina , Krontiras Helen , Guo Zhanfang , Lee Michelle V. , Spies Nicholas C. , Skidmore Zachary L. , Griffith Obi L. , Griffith Malachi , Thomas Shana , Bumb Caroline , Vij Kiran , Bartlett Cynthia Huang , Koehler Maria , Al-Kateb Hussam , Sanati Souzan , Ellis Matthew J.
Published: April 2023

Supplementary Table S1 describes the AE profile, Supplementary S2 shows the results of clinical and radiologic responses.
Supplementary Table 4 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Probe-sets that Best Discriminated between Adenoma and Carcinoma in the IPACTR Cohort and Association with PFS in the COG Cohort
Supplementary Table S4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Authors: Ma Cynthia X. , Gao Feng , Luo Jingqin , Northfelt Donald W. , Goetz Matthew , Forero Andres , Hoog Jeremy , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Anderson Karen S. , Margenthaler Julie , Aft Rebecca , Hobday Timothy , Moynihan Timothy , Gillanders William , Cyr Amy , Eberlein Timothy J. , Hieken Tina , Krontiras Helen , Guo Zhanfang , Lee Michelle V. , Spies Nicholas C. , Skidmore Zachary L. , Griffith Obi L. , Griffith Malachi , Thomas Shana , Bumb Caroline , Vij Kiran , Bartlett Cynthia Huang , Koehler Maria , Al-Kateb Hussam , Sanati Souzan , Ellis Matthew J.
Published: April 2023

This table shows the statistical analysis of significantly changed genes and pathways by treatment with anastrozole alone and by the addition of palbociclib.
Supplementary Table S3-4 caption from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Authors: Ma Cynthia X. , Gao Feng , Luo Jingqin , Northfelt Donald W. , Goetz Matthew , Forero Andres , Hoog Jeremy , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Anderson Karen S. , Margenthaler Julie , Aft Rebecca , Hobday Timothy , Moynihan Timothy , Gillanders William , Cyr Amy , Eberlein Timothy J. , Hieken Tina , Krontiras Helen , Guo Zhanfang , Lee Michelle V. , Spies Nicholas C. , Skidmore Zachary L. , Griffith Obi L. , Griffith Malachi , Thomas Shana , Bumb Caroline , Vij Kiran , Bartlett Cynthia Huang , Koehler Maria , Al-Kateb Hussam , Sanati Souzan , Ellis Matthew J.
Published: April 2023

The caption provides the title and description for the Supplementary Tables S3 adn S4.
Supplementary Fig. 1 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Discriminating gap size (DGS) criterion shows a gap in the distribution of the expression of MHC class II expression in the IPACTR cohort. Each panel plots the rank of expression value in the cohort on the y-axis and the positive quantile transformation (PQT) value on the x-axis. Solid blue circles indicate adrenocortical carcinomas, open red circles indicate adrenocortical adenomas, and black X-marks indicate undetermined histology. In each plot, the gray rectangle highlights the large gap in the distribution that discriminates adenomas from carcinomas which was identified by the DGS criterion.
Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Authors: Ma Cynthia X. , Gao Feng , Luo Jingqin , Northfelt Donald W. , Goetz Matthew , Forero Andres , Hoog Jeremy , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Anderson Karen S. , Margenthaler Julie , Aft Rebecca , Hobday Timothy , Moynihan Timothy , Gillanders William , Cyr Amy , Eberlein Timothy J. , Hieken Tina , Krontiras Helen , Guo Zhanfang , Lee Michelle V. , Spies Nicholas C. , Skidmore Zachary L. , Griffith Obi L. , Griffith Malachi , Thomas Shana , Bumb Caroline , Vij Kiran , Bartlett Cynthia Huang , Koehler Maria , Al-Kateb Hussam , Sanati Souzan , Ellis Matthew J.
Published: April 2023

Supplementary Table S3 provides the result of the 83-gene panel next generation sequencing
Supplementary Figures 1-6 from Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display
Authors: Altmann Annette , Sauter Max , Roesch Saskia , Mier Walter , Warta Rolf , Debus Jürgen , Dyckhoff Gerhard , Herold-Mende Christel , Haberkorn Uwe
Published: April 2023

Supplementary Figure S1: Western blot analysis of protein lysates derived from HNO97 Cells; Supplementary Figure S2: ITGαVβ6 expression in vitro and in situ; Supplementary Figure S3: Binding properties of SFPF-10; Supplementary Figure S4: Evaluation of 125I-SFITGv6 binding to breast- and colon carcinoma cell lines and the internalization and efflux of 125I-SFITGv6 from HNO97 cells; Supplementary Figure S5: Histochemical peptide staining of brain metastasis; Supplementary Figure S6: Histochemical peptide staining of carcinoma-free lymph nodes.
Supplemental Figure 1 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Authors: Offin Michael , Rizvi Hira , Tenet Megan , Ni Andy , Sanchez-Vega Francisco , Li Bob T. , Drilon Alexander , Kris Mark G. , Rudin Charles M. , Schultz Nikolaus , Arcila Maria E. , Ladanyi Marc , Riely Gregory J. , Yu Helena , Hellmann Matthew D.
Published: April 2023

Study selection flow diagram
Supplementary Figure Legend from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

Supplementary Figure Legend
Supplementary Data combined from MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members
Authors: Yan Dan , Parker Rebecca E. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

combined
SupVideo4 from MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members
Authors: Yan Dan , Parker Rebecca E. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Combined
SupVideo3 from MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members
Authors: Yan Dan , Parker Rebecca E. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

100nM MRX-2843
Supporting information from 89Zr-anti-γH2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Authors: Knight James C. , Mosley Michael J. , Bravo Luisa Contreras , Kersemans Veerle , Allen P. Danny , Mukherjee Somnath , O'Neill Eric , Cornelissen Bart
Published: April 2023

Descriptions of therapeutic regimens, PET/CT image acquisition details, tabulated ex vivo biodistribution data, and results of capecitabine therapy monitoring experiments are provided in the supporting information. TABLE S1: Ex vivo biodistribution data acquired at 24 h p.i. of 89Zr-anti-γH2AX-TAT or 89Zr-RIgG-TAT (0.1 MBq µg-1) in 5-FU-treated mice. Values are %ID/g {plus minus} SD. TABLE S2: Ex vivo biodistribution data acquired at 1.5 h p.i. of 18F-FDG in 5-FU-treated mice. Values are %ID/g {plus minus} SD. TABLE S3: Ex vivo biodistribution data acquired at 24 h p.i. of 89Zr-anti-γH2AX-TAT or 89Zr-RIgG-TAT (0.1 MBq µg-1) in gemcitabine-treated mice. Values are %ID/g {plus minus} SD. TABLE S4: Ex vivo biodistribution data acquired at 1.5 h p.i. of 18F-FDG in gemcitabine-treated mice. Values are %ID/g {plus minus} SD. TABLE S5: Ex vivo biodistribution data acquired at 24 h p.i. of 89Zr-anti-γH2AX-TAT or 89Zr-RIgG-TAT (0.01 MBq µg-1) in capecitabine-treated mice. Values are %ID/g {plus minus} SD. TABLE S6: Ex vivo biodistribution data acquired at 1.5 h p.i. of 18F-FDG in capecitabine-treated mice. Values are %ID/g {plus minus} SD. Fig. S1 Representative iTLCs of crude reaction mixtures upon completion of reaction (left) and quality control of the purified product (right) Fig. S2 Monitoring capecitabine therapy with 89Zr-anti-γH2AX-TAT Fig. S3 Monitoring capecitabine therapy with 18F-FDG
SupVideo2 from MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members
Authors: Yan Dan , Parker Rebecca E. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

1uM CO-1686
Supplementary Figure 1. from Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
Authors: Osswald Matthias , Blaes Jonas , Liao Yunxiang , Solecki Gergely , Gömmel Miriam , Berghoff Anna S. , Salphati Laurent , Wallin Jeffrey J. , Phillips Heidi S. , Wick Wolfgang , Winkler Frank
Published: April 2023

Table shows the observed exposure in pharmakokinetic (PK) studies (A), and the dose predicted for GDC-0980 to achieve comparable AUC and Cmax of the compounds used in mice (B). Of note, plasma clearance of GDC-0980 in mice is 6.3 ml/min/kg (16), while that of GNE-317 is 32 ml/min/kg (47).
Supplementary Figure 1 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Authors: Moreno Laura , Perez Cristina , Zabaleta Aintzane , Manrique Irene , Alignani Diego , Ajona Daniel , Blanco Laura , Lasa Marta , Maiso Patricia , Rodriguez Idoia , Garate Sonia , Jelinek Tomas , Segura Victor , Moreno Cristina , Merino Juana , Rodriguez-Otero Paula , Panizo Carlos , Prosper Felipe , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure 1
Supplementary Tables and Figures from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary appendix: Includes 2 tables: (1) summary of analysis results for plasma biomarkers as predictive factors for treatment effect on overall survival; and (2) summary of analysis results for plasma biomarkers as predictive factors for time to progression. A figure legend for the supplemental figures is also included.
Supplementary Tables and Figures TC from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary appendix: Includes 2 tables: (1) summary of analysis results for plasma biomarkers as predictive factors for treatment effect on overall survival; and (2) summary of analysis results for plasma biomarkers as predictive factors for time to progression. A figure legend for the supplemental figures is also included.
Supplementary Data from 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Authors: Lee Helen , Shields Anthony F. , Siegel Barry A. , Miller Kathy D. , Krop Ian , Ma Cynthia X. , LoRusso Patricia M. , Munster Pamela N. , Campbell Karen , Gaddy Daniel F. , Leonard Shannon C. , Geretti Elena , Blocker Stephanie J. , Kirpotin Dmitri B. , Moyo Victor , Wickham Thomas J. , Hendriks Bart S.
Published: April 2023

Fig. S1. MM-302 tumor deposition in preclinical xenografts as a function of HER2 expression. Fig. S2. Preclinical assessment of minimum 64Cu-MM-302 tumor delivery for anti-tumor activity. Fig. S3. Maximum intensity projection images of selected patients with average and rapid clearance of 64Cu-MM-302. Fig. S4. Stability of 64Cu-MM-302 in patients. Fig. S5. Hepatic tumor lesion with similar uptake as normal liver tissue. Fig. S6. Estimated parameter values (k1, k-1, VVF) for lesions from 3 patients who underwent 3 scans. Table S1. Model parameters for tracer kinetic modeling of 64Cu-MM-302 liposome transport into and out of tumors. Table S2. Patient Demographic (n=19). Table S3. Radiation Dosimetry of 64Cu-MM-302 (n=11).
Supplementary Table S3 from Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
Authors: Carbone Carmine , Piro Geny , Simionato Francesca , Ligorio Francesca , Cremolini Chiara , Loupakis Fotios , Alì Greta , Rossini Daniele , Merz Valeria , Santoro Raffaela , Zecchetto Camilla , Zanotto Marco , Di Nicolantonio Federica , Bardelli Alberto , Fontanini Gabriella , Tortora Giampaolo , Melisi Davide
Published: April 2023

Supplementary Table S3. Correlation between HOXB9 expression and clinicopathologic characteristic in bevacizumab treated colorectal cancer patients
Raw data 3 from Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma
Authors: Lin Yusheng , Dong Hongmei , Deng Weilun , Lin Wan , Li Kai , Xiong Xiao , Guo Yi , Zhou Fuyou , Ma Changchun , Chen Yuping , Ren Hongzheng , Yang Haijun , Dai Ningtao , Ma Lang , Meltzer Stephen J. , Yeung Sai-Ching J. , Zhang Hao
Published: April 2023

Raw data 3-Supplementary Zip including supplementary tables with the qRT-PCR data from the patient cohorts with the amplification profile data (validation cohort)
Supplementary Data from PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Authors: Melaiu Ombretta , Mina Marco , Chierici Marco , Boldrini Renata , Jurman Giuseppe , Romania Paolo , D'Alicandro Valerio , Benedetti Maria C. , Castellano Aurora , Liu Tao , Furlanello Cesare , Locatelli Franco , Fruci Doriana
Published: April 2023

This file describes the legend of supplemental figures. It also include the supplemental Table S1
Supplementary Data from Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
Authors: Wilsker Deborah F. , Barrett Allison M. , Dull Angie B. , Lawrence Scott M. , Hollingshead Melinda G. , Chen Alice , Kummar Shivaani , Parchment Ralph E. , Doroshow James H. , Kinders Robert J.
Published: April 2023

Supplemental methods, figures, captions, and references. Supplemental Figure S1. Isotype controls. Supplemental Figure S2. ATM deficiency attenuates pS343-Nbs1 signal induction. Supplemental Figure S3. Comparison of the percent nuclear area positive for γH2AX versus the proportion of cells positive for γH2AX signal. Supplemental Figure S4. pS343-Nbs1 is a sensitive marker of genotoxic agents across different classes. Supplemental Figure S5. Development of nuclear masks for quantitation of DAPI area, nuclear marker expression, and nuclear foci. Supplemental Fig. S6. pS343-Nbs1 and γH2AX calibrators. Supplemental Figure S7. DDR activation in the context of homologous recombination defects. Supplemental Figure S8. Induction of Rad51 and colocalization with cell cycle marker geminin following gemcitabine exposure.
Supplementary Data from Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma
Authors: Davare Monika A. , Henderson Jacob J. , Agarwal Anupriya , Wagner Jacob P. , Iyer Sudarshan R. , Shah Nameeta , Woltjer Randy , Somwar Romel , Gilheeney Stephen W. , DeCarvalo Ana , Mikkelson Tom , Van Meir Erwin G. , Ladanyi Marc , Druker Brian J.
Published: April 2023

Supplementary Figures
Supplementary Figures 1-4 from MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer
Authors: Saigi Maria , Alburquerque-Bejar Juan J. , Mc Leer-Florin Anne , Pereira Carolina , Pros Eva , Romero Octavio A. , Baixeras Nuria , Esteve-Codina Anna , Nadal Ernest , Brambilla Elisabeth , Sanchez-Cespedes Montse
Published: April 2023

Supplementary Fig. 1. A, Western blot showing ectopic and transient expression of the LKB1 protein in the indicated cell lines; Supplementary Fig. 2. A, Profile of JAK2 mutations in NSCLC primary tumors, from the cBioPortal for Cancer Genomics (www.cbioportal.org); Supplementary Fig. 3. Western blot depicting the levels of the indicated proteins and cell lines, upon treatment with IFNγ, at a concentration of 30 ng/μL for 6 h. ACTIN and TUBULIN, protein-loading controls; Supplementary Fig. 4. Enriched gene ontology classifications (P<0.05) for the up-regulated genes in the MET-Sign and IFN-Sign.
Figure S6 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S6. Effects of PI3K/mTOR pathway inhibition in NOTCH1WT HNSCC with and without NOTCH1 knock out (KO). Two NOTCH1WT HNSCC cell lines (FaDU and MDA686LN), parental cell lines, and NOTCH1 KO cell lines were treated with GSK2126458 (GSK212). A and B. The CellTiter-Glo assay was used to assess the viability of cells treated for 72 hours with the indicated concentrations of GSK212. C and D. Annexin V/propidium iodide staining was used to assess the apoptosis of cells treated with 50 nM GSK212 for 48 hours. Values are the means {plus minus} standard deviations of three independent experiments; n.s., not significant, unpaired two-tailed Student t-test. (E) Western blot analysis of apoptotic markers was performed after treatment with the indicated concentrations of GSK212 for 48 hours.
Supplementary Figures from Clonal Structures of Regionally Synchronous Gastric Adenomas and Carcinomas
Authors: Jung Seung-Hyun , Kim Shin Young , An Chang Hyeok , Lee Sung Hak , Jung Eun Sun , Park Hyeon-Chun , Kim Min Sung , Chung Yeun-Jun , Lee Sug Hyung
Published: April 2023

Supplementary Fig. S1. Histology of synchronous GAs and GCs. Microscopic features of STC GA01-15 and STC GC01-15 are shown. Black boxes indicate GA or GC lesion. Supplementary Fig. S2. Immunohistochemical staining of MLH1 in STC15. Supplementary Fig. S3. Mutation rate of GA and GC genomes. Supplementary Fig. S4. Genomic similarities of MSS GA and MSS GC. Supplementary Fig. S5. Genomic similarities of MSI GA and MSI GC. Supplementary Fig. S6. Multi-region targeted deep sequencing of collision tumors (STC04 and STC07). Supplementary Fig. S7. High-level amplifications and homozygous deletions. Supplementary Fig. S8. Chromothripsis in STC. Supplementary Fig. S9. Copy-neutral LOH on chromosome 8 in STC15. Supplementary Fig. S10. ClonEvol analysis of 13 gastric cancer genomes.
Supplementary Table, Supplementary Figure Legends from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
Authors: McKay Rana R. , Bossé Dominick , Gray Kathryn P. , Michaelson M. Dror , Krajewski Katherine , Jacene Heather A. , Walsh Meghara , Bellmunt Joaquim , Pomerantz Mark , Harshman Lauren C. , Choueiri Toni K.
Published: April 2023

supplemental table and legend for suppl figures
Table S4 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Statistical summary of immune populations from CYTOF data
Figure S5 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
Authors: McKay Rana R. , Bossé Dominick , Gray Kathryn P. , Michaelson M. Dror , Krajewski Katherine , Jacene Heather A. , Walsh Meghara , Bellmunt Joaquim , Pomerantz Mark , Harshman Lauren C. , Choueiri Toni K.
Published: April 2023

Figure for online supplement
Figure S4 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
Authors: McKay Rana R. , Bossé Dominick , Gray Kathryn P. , Michaelson M. Dror , Krajewski Katherine , Jacene Heather A. , Walsh Meghara , Bellmunt Joaquim , Pomerantz Mark , Harshman Lauren C. , Choueiri Toni K.
Published: April 2023

Figure for online supplement
Figure S3 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
Authors: McKay Rana R. , Bossé Dominick , Gray Kathryn P. , Michaelson M. Dror , Krajewski Katherine , Jacene Heather A. , Walsh Meghara , Bellmunt Joaquim , Pomerantz Mark , Harshman Lauren C. , Choueiri Toni K.
Published: April 2023

Figure for online supplement
Figure S2 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
Authors: McKay Rana R. , Bossé Dominick , Gray Kathryn P. , Michaelson M. Dror , Krajewski Katherine , Jacene Heather A. , Walsh Meghara , Bellmunt Joaquim , Pomerantz Mark , Harshman Lauren C. , Choueiri Toni K.
Published: April 2023

Figure for online supplement
Figure S4 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Tsne plots for EOMES, CD69,CD4, and FOXP3 on T cells
Table S1 and S2 from T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
Authors: Deniger Drew C. , Pasetto Anna , Robbins Paul F. , Gartner Jared J. , Prickett Todd D. , Paria Biman C. , Malekzadeh Parisa , Jia Li , Yossef Rami , Langhan Michelle M. , Wunderlich John R. , Danforth David N. , Somerville Robert P.T. , Rosenberg Steven A.
Published: April 2023

Clinical details (S1) and neoepitope details (S2).
Figure S2 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Checkpoint expression between matched biopsies
Figure S1 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Checkpoint expression in PD-1 negative biopsies and VISTA expression in tumors
Supplementary text from Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells
Authors: Zhao Xueheng , Brusadelli Marion G. , Sauter Sharon , Butsch Kovacic Melinda , Zhang Wujuan , Romick-Rosendale Lindsey E. , Lambert Paul F. , Setchell Kenneth D.R. , Wells Susanne I.
Published: April 2023

Supplementary methods section
Supplemental Tables from Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas
Authors: Lu Chia-Feng , Hsu Fei-Ting , Hsieh Kevin Li-Chun , Kao Yu-Chieh Jill , Cheng Sho-Jen , Hsu Justin Bo-Kai , Tsai Ping-Huei , Chen Ray-Jade , Huang Chao-Ching , Yen Yun , Chen Cheng-Yu
Published: April 2023

Table S1 Full list of included TCIA glioma subjects for the training of the machine-learning models (KPS = Karnofsky Performance Scale) Table S2 MRI data integrity of the training dataset Table S3 Full list of included subjects as an independent validation dataset Table S4 The formulae for the calculation of primary radiomic features.
Table S3 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Summary of individual CTCs per patient with percentage of the genome covered by a copy number segment and percentage of genes that are altered.
Supplementary Table S8. from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S8. Patient characteristics of bladder specimens used for figure 4B, 4C, and 4G.
Supplementary Table S7 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S7. Univariate and multivariate Cox proportional hazard regression models of the TCGA (A), Lindgren (B), Sjodahl (C), and Kim (D), data sets using CPT1B gene expression. Univariate Cox proportional hazard regression analysis showed that CPT1B expression yields a Hazard ratios below 1 in TCGA, Lindgren, and Sjodahl, and is significantly associated with survival in TCGA cohort. The multivariate models after adjustment for other factors such as sex, age and tumor stage, revealed that low (HR less than 1) CPT1B expression was significantly associated with an increased risk of death in TCGA. Hazard ratios (HRs) derived from the Cox proportional hazards models are expressed with 95% confidence intervals (CIs) and p-values. For all analyses, p-value <0.05 was considered clinically significant and are highlighted in green.
Supplementary Table S2 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Table S2. List of gene-specific primers used for q-PCR.
Supplementary Figure S7 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S7. mRNA expression of CPT1B in the Kim (p<2.7Ã-10-4), Sjodahl (p<2.5Ã-10-7), and Lindgren (p<2.8Ã-10-13) cohorts.
Supplemental Table S5 from Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer
Authors: Kim Tae Won , Peeters Marc , Thomas Anne , Gibbs Peter , Hool Kristina , Zhang Jianqi , Ang Agnes Lee , Bach Bruce Allen , Price Timothy
Published: April 2023

Plasma-SelectTM Sequence Mutations Gene List
Supplementary Tables from On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Authors: Brown Benjamin P. , Zhang Yun-Kai , Westover David , Yan Yingjun , Qiao Huan , Huang Vincent , Du Zhenfang , Smith Jarrod A. , Ross Jeffrey S. , Miller Vincent A. , Ali Siraj , Bazhenova Lyudmila , Schrock Alexa B. , Meiler Jens , Lovly Christine M.
Published: April 2023

Supplementary Tables
Supplementary Appendix from Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Authors: Gallois Claire , Taieb Julien , Le Corre Delphine , Le Malicot Karine , Tabernero Josep , Mulot Claire , Seitz Jean-François , Aparicio Thomas , Folprecht Gunnar , Lepage Côme , Mini Enrico , Van Laethem Jean-Luc , Emile Jean-François , Laurent-Puig Pierre
Published: April 2023

Supplementary Appendix shows the PETACC-8 study investigators
Table S8 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S8. Clinical characteristics of patients according to the GC-SVM classifier in the training, internal and external validation cohorts.
Table S5 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S5. Univariable analysis of the GC-SVM classifier, patient characteristics, immunomarker expression, and disease-free survival in the internal and external cohorts.
Supplementary Tables from PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
Authors: Chung Elaine Y. , Mai Yun , Shah Urvi A. , Wei Yongqiang , Ishida Elise , Kataoka Keisuke , Ren Xiaoxin , Pradhan Kith , Bartholdy Boris , Wei Xiaolei , Zou Yiyu , Zhang Jinghang , Ogawa Seishi , Steidl Ulrich , Zang Xingxing , Verma Amit , Janakiram Murali , Ye B. Hilda
Published: April 2023

Supplementary Tables Table S1. List of antibodies used in Western blotting and flow cytometry analyses. Table S2. List of qRT-PCR primers.
Table S3 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S3. Univariable analysis of the GC-SVM classifier, patient characteristics, immunomarker expression, and survival in the training cohort.
Figure S6 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Figure S6. Kaplan-Meier survival analysis of OS for patients in the external validation cohort according to the GC-SVM classifier stratified by clinicopathological risk factors. P-values were calculated by log-rank test.
Supplementary Figure Legends from Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Authors: Margolin Kim , Morishima Chihiro , Velcheti Vamsidhar , Miller Jeffrey S. , Lee Sylvia M. , Silk Ann W. , Holtan Shernan G. , Lacroix Andreanne M. , Fling Steven P. , Kaiser Judith C. , Egan Jack O. , Jones Monica , Rhode Peter R. , Rock Amy D. , Cheever Martin A. , Wong Hing C. , Ernstoff Marc S.
Published: April 2023

Supplementary Figure 1-3 Legends
Figure S3 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Figure S3. Kaplan-Meier survival analysis of DFS for patients in the internal validation cohort according to the GC-SVM classifier stratified by clinicopathological risk factors. P-values were calculated by log-rank test.
Supplemental Figure 1 from Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling
Authors: Griewank Klaus G. , Koelsche Christian , van de Nes Johannes A.P. , Schrimpf Daniel , Gessi Marco , Möller Inga , Sucker Antje , Scolyer Richard A. , Buckland Michael E. , Murali Rajmohan , Pietsch Torsten , von Deimling Andreas , Schadendorf Dirk
Published: April 2023

Supplemental Figure 1. Copy number alterations in blue nevus-like melanoma
Supplementary Information from TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer
Authors: Blee Alexandra M. , He Yundong , Yang Yinhui , Ye Zhenqing , Yan Yuqian , Pan Yunqian , Ma Tao , Dugdale Joseph , Kuehn Emily , Kohli Manish , Jimenez Rafael , Chen Yu , Xu Wanhai , Wang Liguo , Huang Haojie
Published: April 2023

Supplementary Figures and Tables. /// Supplementary Figure 1. TP53 mutation status in human prostate cancer. /// Supplementary Figure 2. Genotypic and histological characterization of Pten/Trp53/ERG-altered mouse prostates. /// Supplementary Figure 3. Immunohistochemistry and immunofluorescent co-staining of key markers in serially-sectioned mouse prostate tissues. /// Supplementary Figure 4. Transcriptomic characterization of the Pten/Trp53/ERG-mutated mouse prostates. /// Supplementary Figure 5. Western blot analysis of expression of ERG downstream genes and E2F1 targets in human prostate cancer cells. /// Supplementary Figure 6. Analysis of expression of ERG-regulated genes and ERG chromatin binding at these gene loci in human prostate cancer PC-3 cells. /// Supplementary Figure 7. Palbociclib and enzalutamide treatment optimization in human prostate cancer cell lines. /// Supplementary Figure 8. Characterization of LNCaP-RF xenografts and mouse tumor-derived allografts. /// Supplementary Table 1. shRNA sequences. /// Supplementary Table 2. RT-qPCR primer sequences. /// Supplementary Table 3. ChIP-qPCR primer sequences. /// Supplementary Table 4. PCR genotyping primer sequences. /// Supplementary Table 5. Raw staining index scores for AR and ERG IHC of mCRPC human tissue microarray. /// References
Supplementary Tables from Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Authors: Hagemann Urs B. , Ellingsen Christine , Schuhmacher Joachim , Kristian Alexander , Mobergslien Anne , Cruciani Véronique , Wickstroem Katrine , Schatz Christoph A. , Kneip Christoph , Golfier Sven , Smeets Roger , Uran Steinar , Hennekes Hartwig , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Mumberg Dominik , Ziegelbauer Karl , Cuthbertson Alan S.
Published: April 2023

The file contains Supporting Tables.
Table S1 from Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Authors: Atkins Michael B. , Hodi F. Stephen , Thompson John A. , McDermott David F. , Hwu Wen-Jen , Lawrence Donald P. , Dawson Nancy A. , Wong Deborah J. , Bhatia Shailender , James Marihella , Jain Lokesh , Robey Seth , Shu Xinxin , Homet Moreno Blanca , Perini Rodolfo F. , Choueiri Toni K. , Ribas Antoni
Published: April 2023

Prespecified Dose-Limiting Toxicities
Figure S5 from Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Authors: L'Italien Lawrence , Orozco Olivia , Abrams Tinya , Cantagallo Lisa , Connor Anu , Desai Jayesh , Ebersbach Hilmar , Gelderblom Hans , Hoffmaster Keith , Lees Emma , Maacke Heiko , Schleyer Siew , Skegro Darko , Lee-Hoeflich Si Tuen
Published: April 2023

FcgR1/FcgR3 gene expression analysis of in vitro generated mast cells
Supplementary Figure 3 from CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC
Authors: Liu Youyi , Liu Lijuan , Zhou Yan , Zhou Ping , Yan Qiujin , Chen Xiaobei , Ding Shuang , Zhu Fan
Published: April 2023

The proliferation rate of HCC cells is enhanced by CKLF1.
Supplemental Figure 1-5 from IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
Authors: Li Ji , Ybarra Ryan , Mak Judy , Herault Aurelie , De Almeida Patricia , Arrazate Alfonso , Ziai James , Totpal Klara , Junttila Melissa R. , Walsh Kevin B. , Junttila Teemu T.
Published: April 2023

Fig. S1. Subset analysis of tumor infiltrating and splenic CD8+ T cells after treatment with anti-HER2/CD3 TDB; Fig. S2. Anti-HER2/CD3 TDB increases intra-tumoral lymphocyte infiltration in Fo5 allograft model of HER2 overexpressing breast cancer within immunocompetent mice; Fig. S3. Anti-HER2/CD3 treatment did not induce peripheral CD8+ T cell proliferation; Fig. S4. Anti-HER2/CD3 TDB induced acute release of pro-inflammatory cytokines in serum; Fig. S5. Induction of CXCR3 ligands within Fo5 tumors in response to anti-HER2/CD3.
Table S1 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Drug concentrations corresponding to each effective concentration
Table S7 from Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas
Authors: Zhu Haibo , Guo Jing , Shen Yutao , Dong Wei , Gao Hua , Miao Yazhou , Li Chuzhong , Zhang Yazhuo
Published: April 2023

The TNF-α expression level of the two groups
Figure S3 from Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer
Authors: Xu MengMeng , Casio Michael , Range Danielle E. , Sosa Julie A. , Counter Christopher M.
Published: April 2023

Supplementary Figure 3. Number of lung metastases in TBP mice after A) 8 weeks or B) 24 weeks of the indicated drug treatments.